[OneMedForum] Immunocellular Therapeutics
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
Articles by vanderson
[OneMedForum] OrSense: Non-Invasive Blood Monitoring Solutions
Israel-based OrSense is attempting to increase patient compliance with a non-invasive continuous glucose monitor based on optical technology.
[OneMedForum] Jaleva Pharmaceuticals
One company presenting at the conference is San Diego-based Jaleva Pharmaceuticals, which has developed a resin-based delivery vehicle for topical medications.
Keryx Biopharma: Well-Funded Comeback Story with Multiple Catalysts
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
EyeGate Raises $22.6M In Venture Funding
The money will be used to further the company’s development of EGP-437 to treat dry eye syndrome.
Enzon and Sopherion Make Breast Cancer Progress
Two biopharmaceutical companies took a step forward this week with their pipelines for advanced breast cancer.
As Seasonal Flu Ramps Up, NexBio Begins Phase II Trial for DAS181
DAS181 is formulated to prevent the influenza virus from entering cells in the respiratory tract.
NeoPharm to Investigate Treatment for Deadly Lung Disease
The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year.
Implantable Weight-Loss Device Receives CE Mark Approval
GI Dynamics has received European CE mark approval to commercialize a non-surgical device for the management of obesity and Type 2 diabetes.